이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

SweetSpot - 무칼로리 감미료가 건강에 미치는 영향

2026년 11월 5일 업데이트: Monica Mars, Wageningen University

SweetSpot - 건강한 성인에서 비영양 감미료가 포도당 조절, 장내 미생물군 및 장 호르몬 분비에 미치는 영향: 완전히 통제된 교차 중재 연구

The aim of the study is to investigate the effect of non-nutritive sweeteners on glucose regulation. Secondary objectives are to investigate the effect of NNS on gut microbiome, gut hormone secretion, sweet taste sensitivity and preference, and the excretion of NNS in urine.

연구 개요

상세 설명

Sugar intake has increased over the years, simultaneously with the prevalence of overweight and obesity. To decrease sugar intake, consumption of non-nutritive sweeteners (NNS) has increased and opinions on its use remain divided. A fully controlled dietary intervention using a NNS mixture and dose that is similar to real-life intake, is therefore necessary to advance our understanding of the potential effects of NNS on glucose regulation, gut microbiome, and gut hormone secretion under real-life conditions.

The aim of this study is to investigate the effect of non-nutritive sweeteners on glucose regulation. Secondary objectives are to investigate the effect of NNS on gut microbiome, gut hormone secretion, sweet taste sensitivity and preference, and the excretion of NNS in urine.

To do this, a single blind, fully controlled dietary intervention with a cross-over design will be performed. The study will consist of 2x8 weeks of intervention, with a washout of > 6 weeks in between. The study population will be 60 healthy adults aged 45-79, with a BMI between 20-35 kg/m2.

The study will consist of a fully controlled diet of two 8-week intervention periods (2 weeks run-in + 6 weeks intervention). The diets differ in the presence of non-nutritive sweeteners (NNS): NNS-diet versus non-NNS diet, where additional NNS are added to the NNS-diet.

The primary outcome measure will be the within person difference in blood glucose incremental area under the curve following a 75 g glucose tolerance test between the NNS diet and the non-NNS diet. Secondary outcome measures are the effect of NNS on Matsuda index, insulin response, blood lipid profile, and gut hormone secretion will be determined. The effect of NNS on small- and large intestinal microbiome will be investigated by a change in composition, functionality, and short chain fatty acid content. The effect of NNS on sweet taste sensitivity, preference, and liking will be investigated, as well as the excretion of NNS in urine and saliva.

The total time invested by participants is around 85 hours. Participants are restricted for 16 weeks in their eating habits, since they follow a fully controlled diet prepared by the research facility. Participants will visit the research facility in total 38 times. In total, ~ 603 mL of blood will be drawn by experienced nurses over the entire RCT (>6 month period). During DEXA scans, participants will receive a total of about 0.006 mSv of radiation.

Invasive measurements that participants can experience as burden are collection of faecal and urine samples, and finding back the Simba capsules in the stool. Non-invasive measurements for participants are wearing the CGM, wearing the ActiGraph, consuming the blue cakes, and performing sensory tests.

연구 유형

중재적

등록 (추정된)

60

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Gelderland
      • Wageningen, Gelderland, 네덜란드, 6708WG
        • Wageningen University & Research

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

45년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Age 45-79 years;
  • BMI of 20-35 kg/m2;
  • Having veins suitable for placement of a venflon catheter.

Exclusion Criteria:

  • Diseases or prior surgeries affecting the stomach, liver, kidneys or intestines (allowed i.e. appendectomy);
  • Cardiovascular diseases (e.g. heart failure) or cancer (e.g. non-invasive skin cancer allowed);
  • Diagnosed with type 1 or type 2 diabetes;
  • Drug treated thyroid diseases (well substituted hypothyroidism is allowed for inclusion);
  • HbA1c level >6.5% (>48 mmol/mol), as measured during the screening visit;
  • Anaemia defined as Hb concentrations <8.5 mmol/L for men and <7.5 mmol/L for women via finger prick;
  • Regular use of/receiving medication interfering with research outcomes (as judged by research physician), such as use of glucose lowering drugs, insulin, or use of medication that impacts the gastro-intestinal system;
  • Use of antibiotics over the last 3 months before study start;
  • Donated blood within 2 months prior to the screening;
  • Food allergies, intolerances (including lactose/gluten intolerance) for products used in the study design and/or dietary restrictions interfering with the study (including special diets and eating disorders);
  • Followed a diet that can interfere with the study outcomes within 1 month prior to the screening (e.g. ketogenic, sugar free, carbohydrate free);
  • Not willing to eat all products in the study diet, including eggs and dairy. Vegetarian is possible;
  • Not willing to consume non-nutritive sweeteners;
  • Not willing to quit the use of supplements that can interfere with the study outcomes (e.g. pre- or probiotics).
  • Intention to change the intensity of exercise during the study period or planning to join a intensive sport event (e.g. marathon or triathlon);
  • Intention to lose or gain weight;
  • Working night shifts regularly;
  • Smoking regularly
  • Use of soft and/or hard drugs (cannabis included);
  • Abuse of alcohol (defined as >14 glasses (women) or >21 glasses (men) of alcoholic beverages per week);
  • Being pregnant or lactating or planning to become pregnant;
  • Inability to understand study information and/or communicate with staff;
  • Participation in another study that involves an intervention within two months prior to the intervention;
  • Working or doing a thesis/internship at the division of Human Nutrition & Health, or the Food, Health & Consumer Research group of Wageningen Food & Biobased Research.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 다른
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
다른: NNS / no-NNS

In this arm, participants will first receive the NNS diet, and the no-NNS diet in the second study period.

Fully controlled diet with added mixture of non-nutritive sweeteners. The mixture consist of 6 different non-nutritive sweeteners: acesulfame-K, aspartame, cyclamate, saccharin, sucralose, and rebaudioside A (stevia).

Fully controlled diet without any non-nutritive sweeteners added.

다른: No-NNS / NNS

In this arm, participants will first receive the no-NNS diet, and the NNS diet in the second study period.

Fully controlled diet with added mixture of non-nutritive sweeteners. The mixture consist of 6 different non-nutritive sweeteners: acesulfame-K, aspartame, cyclamate, saccharin, sucralose, and rebaudioside A (stevia).

Fully controlled diet without any non-nutritive sweeteners added.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Difference in change in 2h iAUC glucose after 6 weeks between the intervention and the control.
기간: Week 2 and week 8 in both intervention periods (4 times in total)

The primary outcome measure is the difference in change in iAUC of blood glucose levels following a 2-hour oral glucose tolerance test (OGTT) after six weeks between the intervention period and the control period.

Week 2 and week 8 in both intervention periods (4 times in total)

2차 결과 측정

결과 측정
측정값 설명
기간
Matsuda index
기간: Week 2 and week 8 in both intervention periods (4 times in total)

Matsuda index after an OGTT

Week 2 and week 8 in both intervention periods (4 times in total)
Fasting blood glucose
기간: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Fasting blood glucose

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Fasting blood insulin
기간: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Fasting blood insulin

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Postprandial insulin response
기간: Week 2 and 8 in both intervention periods (4 times in total).

2-hour iAUC blood insulin during OGTT

Week 2 and 8 in both intervention periods (4 times in total).
Postprandial glucose response after a breakfast
기간: Week 7 in both study periods (2 times in total)

Postprandial blood glucose responses (PPGR) following specific meals measured by CGM.

Week 7 in both study periods (2 times in total)
Blood lipid profile
기간: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

All circulating blood lipids, including all cholesterol types, triglycerides, and free fatty acids (FFAs).

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Gut microbiota composition
기간: Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.

Microbiota composition in faeces

Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
Gut microbiota function
기간: Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.

Microbiota functionality measured in faeces

Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
Microbial metabolites
기간: Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.

Microbial metabolites measured in faeces

Average of three samples per timepoint. Measured at baseline & 2 times per intervention period (week 2 and week 8). 15 samples over 5 timepoints in total.
Small intestinal microbiota composition
기간: Week 7 of both intervention periods (2 times in total).

Microbiota composition of the small intestine measured with Simba Capsules

Week 7 of both intervention periods (2 times in total).
Gastro-intestinal transit time
기간: Baseline & week 7 of both intervention periods (3 times in total).

Gastro-intestinal transit time measured with blue muffins.

Baseline & week 7 of both intervention periods (3 times in total).
Oral microbiome composition & function
기간: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Oral microbiome composition & function measured in saliva

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Postprandial GLP-1 secretion
기간: Week 2 and 8 of both intervention periods (4 times in total).

3-hour AUC of GLP-1 during an OGTT.

Week 2 and 8 of both intervention periods (4 times in total).
Postprandial GIP secretion
기간: Week 2 and 8 of both intervention periods (4 times in total).

3-hour AUC of GIP during an OGTT.

Week 2 and 8 of both intervention periods (4 times in total).
Sweetness-liker phenotype
기간: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Sweetness-liker phenotype, with the sweetness liker test.

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Sweetness preference & liking
기간: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Sweetness preference & liking measured on a rank-rating scale. Preference will be determined using the categorical values from the rank-rating scale (1-5), and liking will be determined using the continuous values from the rank-rating scale (0-100).

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Sweet taste sensitivity
기간: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Sweet taste sensitivity measured on a 100mm Visual Analogue Scale. A higher score for all solutions indicates a higher sweet taste sensitivity.

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.
Excretion of NNS in urine
기간: Baseline, week 2 and week 8 in intervention period 1, and every two weeks in intervention period 2 (7 times in total).

Excretion of NNS in urine

Baseline, week 2 and week 8 in intervention period 1, and every two weeks in intervention period 2 (7 times in total).
Excretion of NNS in saliva
기간: Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

Excretion of NNS in saliva

Baseline & 2 times per intervention period (week 2 and week 8). 5 times in total.

기타 결과 측정

결과 측정
측정값 설명
기간
Anthropometrics
기간: Baseline

Measured as weight (kg), height (m), waist circumference (cm), and hip circumference (cm). Weight and height will be combined to report BMI in kg/m^2.

Baseline
Body composition
기간: Baseline & week 8 of both intervention periods (3 times in total).

Body composition as measured by DEXA (Dual Energy X-ray Absorptiometry).

Baseline & week 8 of both intervention periods (3 times in total).
Habitual food intake
기간: Baseline

Habitual dietary intake assessment with a food frequency questionnaire (FFQ).

Baseline
Physical activity level
기간: Baseline.

Physical activity level by the Short Questionnaire to Assess Health-enhancing physical activity (SQUASH).

Baseline.
Habitual NNS consumption
기간: Baseline

Habitual NNS consumption by questionnaire

Baseline
Gastro-intestinal symptoms
기간: Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.

Gastro-intestinal symptoms by GSRS questionnaire.

Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.
Satiety
기간: Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.

Satiety questionnaire, adapted from the Control of Eating Questionnaire.

Once during the characterisation period (1 week), and every week during the first intervention period (8 weeks) and every week during the second intervention period (8 weeks). In total up to 17 weeks.
Genetic variation
기간: Baseline

Single Nucleotide Polymorphisms (SNPs) in genes relevant collected using buffycoat.

Baseline
Taste function
기간: Baseline

Measure the ability to recognize the basic tastes in different concentrations, assessed with validated Taste Strips.

Baseline

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 2월 23일

기본 완료 (추정된)

2027년 3월 26일

연구 완료 (추정된)

2027년 3월 26일

연구 등록 날짜

최초 제출

2026년 1월 13일

QC 기준을 충족하는 최초 제출

2026년 1월 13일

처음 게시됨 (실제)

2026년 1월 23일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 5일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다